贝兰他马布 (Belantamab mafodotin) 用于治疗多发性骨髓瘤
Albert Oriol1, Gladys Ibarra1, Jordi Loscos2
1Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias I Pujol, Badalona, Spain.
Expert opinion on biological therapy
|October 15, 2025
概括
贝兰他马布 (Belantamab mafodotin) 是一种BCMA导向的抗体-药物联合体,它显示出作为CAR-T治疗复发性多发性髓瘤的可获得替代方案的前景. 它独特的形状提供了好处,尽管眼部毒性需要管理.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤 (MM) 治疗的进步需要新药来治疗复发性疾病.
- 针对BCMA的CAR-T疗法提供了更好的结果,但也有局限性.
- 贝兰他马布 (Belantamab mafodotin) 提供了一个新的治疗选择.
研究的目的:
- 审查贝兰他马布 (Belantamab) 的作用机制,疗效和安全性.
- 评估其在多发性骨髓瘤治疗的不断变化的格局中的作用.
- 评估其作为CAR-T疗法的替代品的潜力.
主要方法:
- 审查临床试验数据和科学文献.
- 分析贝兰他马布 (Belantamab) 的疗效和安全性.
- 与现有的和新兴的多发性骨髓瘤疗法进行比较.
主要成果:
- 贝兰他马布 (Belantamab mafodotin) 在组合疗法中显示出显著的益处.
- 它提供现成的可用性和独特的作用机制.
- 可管理的眼部毒性 (角膜病变) 是一个关键的不良事件.
结论:
- 贝兰他马布 (Belantamab mafodotin) 是多发性骨髓瘤治疗武器库中一个有价值的补充.
- 它的安全性,特别是较低的感染风险,支持在各种患者群体中使用它.
- 进一步的研究正在探索将其整合到前线治疗中.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
7.2K
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
13.7K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
